Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis
- 11 April 2024
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 111961
Abstract
No abstract availableKeywords
Funding Information
- QingHai Science and Technology Department
This publication has 47 references indexed in Scilit:
- Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancerCancer Immunology, Immunotherapy, 2023
- A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerBreast Cancer Research and Treatment, 2023
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerJAMA Oncology, 2020
- ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)Annals of Oncology, 2020
- Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 studyAnnals of Oncology, 2020
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerJAMA Oncology, 2020
- Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast CancerDrugs, 2020
- Thyroid function following breast cancer chemotherapy: A systematic reviewJournal of Cellular Biochemistry, 2019
- Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical managementCancer, 2018
- Thyroid dysfunctions secondary to cancer immunotherapyJournal of Endocrinological Investigation, 2017